Anne Tomm

Mrs. Anne Tomm

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
ATAnne Tomm
Anne Tomm
ATAlena G. Thiele
Alena G. Thiele
CRCarmen Rohde
Carmen Rohde
SKStefanie Kirmse
Stefanie Kirmse
Wieland KiessWieland Kiess
Wieland Kiess
SBSkadi Beblo
Skadi Beblo
Due to newborn screening and early treatment, patients with phenylketonuria (PKU) and mild hyperphenylalaninemia (mHPA) develop largely normal, in terms of IQ testing and academic attainment. However, the impact of metabolic control in various stages of development on more complex cognitive abilities, i.e. executive functions (EF), is still unclear. EFs were tested in 28 patients with PKU/mHPA, aged 8-17 years, identified by newborn screening and continuously treated. The relation to current (testing day & past 10 phenylalanine (Phe) values) and long-term metabolic control (age periods: childhood 10 years, lifetime Phe) was analyzed. EFs were in the lower normative range (IQR of T-values: 47.35-51.00). Patients reaction time was significantly slower than the population mean (divided attention/TAP: median 40, p < 0.01). Both, long-term and current metabolic control correlated with performance in EF tests: Higher current Phe impaired reaction times (Go/No-Go, r = -0.387; working memory, r = -0.425; p < 0.05) and performance in planning ability (ToL r = -0.465, p < 0.01). Higher long-term Phe values both in childhood and adolescence mainly affected attention (omissions/TAP r = -0.357 and - 0.490, respectively, both p < 0.05) as well as planning ability (ToL r = -0.422 and - 0.387, adolescence and lifetime, p < 0.05). Current and long-term metabolic control in PKU/mHPA, including the adolescent period, influence EFs, especially affecting reaction time and planning abilities. This should be taken into account in patient counselling.

28 November 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
CRCarmen Rohde
Carmen Rohde
ATAlena Gerlinde Thiele
Alena Gerlinde Thiele
ATAnne Tomm
Anne Tomm
DLDinah Lier
Dinah Lier
KEKathrin Eschrich
Kathrin Eschrich
SBSkadi Beblo
Skadi Beblo
Background: Maternal phenylketonuria (PKU) syndrome, leading to severe psychomotor retardation, microcephaly, cardiac defects and undergrowth, affects the unborn children of mothers with PKU with insufficient metabolic control during pregnancy. To improve long-term outcomes, a specific prevention program was developed. Methods: We designed a group training program for young women with PKU (>14 years) and their partners. Knowledge regarding PKU therapy and pregnancy was evaluated by a specifically developed multiple-choice questionnaire. In addition, scores of anxiety and depression were evaluated. Results: Patients (n = 20) and their partners (n = 13) significantly improved their knowledge after participation (correct answers: patients—86% vs. 90%, p = 0.003; partners—78% vs. 89%, p = 0.012). Females significantly improved their knowledge about diet (90% vs. 100%, p = 0.035) and metabolism (91% vs. 100%, p = 0.016), but not concerning gynecological topics. Patients’ median depression scores were within the normative range, with a slight decrease over time (6 points vs. 4 points, p = 0.836). Patients’ anxiety score remained stable over time (5.5 vs. 5, p = 0.247). Of trained mothers with PKU, four pregnancies with ideal metabolic control and healthy offspring could be observed. Conclusion: We suggest the inclusion of specific training programs in the standard care of female young adults with PKU, including for their partners.

12 March 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
ATAnne Tomm
Anne Tomm
ATAlena G. Thiele
Alena G. Thiele
CRCarmen Rohde
Carmen Rohde
HSHaiko Schlögl
Haiko Schlögl
Wieland KiessWieland Kiess
Wieland Kiess
SBSkadi Beblo
Skadi Beblo
Background/Objectives: Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by phenylalanine hydroxylase deficiency, resulting in highly elevated blood phenylalanine (Phe) concentrations, leading to neurotoxic effects. Despite advancements in treatment, adult patients with PKU may experience impairments in executive functions (EFs). This study investigates the influence of metabolic control across different life stages on EFs and sociodemographic outcomes in adult PKU. Methods: We conducted a monocentric study with 36 early-diagnosed and treated PKU patients (mean age: 34.8 years). EFs were assessed using the Test Battery for Attentional Performance (TAP) and the Tower of London (TL-D). Metabolic data were extracted from medical records, focusing on childhood and adulthood metabolic control, including Phe fluctuations. Sociodemographic data were collected via questionnaires. Statistical analyses explored relationships between EFs, metabolic control, and sociodemographic data. Results: EFs in the cohort were within the lower average range. Significant negative correlations could be observed between EF performance and dried blood Phe concentrations during childhood (ages 0–10 years) as well as current Phe concentrations and Phe variation. Elevated childhood Phe concentrations were associated with lower educational attainment. Sociodemographic characteristics, such as employment status and living arrangements, aligned with those of the general population. Conclusions: Optimal cognitive development in PKU requires good metabolic control, particularly in early childhood. In adulthood, while dietary restrictions may be relaxed, maintaining low and stable Phe concentrations is crucial for EFs. Consistent monitoring and tailored therapeutic approaches throughout life seem essential for optimizing metabolic and neurocognitive outcome in PKU.

19 April 2023 in Kinder- und Jugendmedizin
Verified
Journal Article
Closed access
PDF file
ATAnne Tomm
Anne Tomm
FKFranziska Kopp
Franziska Kopp
MGMiriam Gutschke
Miriam Gutschke
SKSusanne Krystek
Susanne Krystek
ZUSAMMENFASSUNG: Psychische Auffälligkeiten bei Kindern und Jugendlichen mit Diabetes Typ 1 (DT1) oder deren primären Bezugspersonen erschweren die Behandlung des Diabetes und erhöhen das Risiko von Folgekomplikationen. Dazu zählen auch diabetesbezogene Ängste wie die Hypoglykämieangst. Diese kann zu maladaptiven Verhaltensweisen führen, die sich negativ auf das Diabetesmanagement auswirken. Zudem werden das emotionale Wohlbefinden und die Lebensqualität von Betroffenen eingeschränkt. Das frühzeitige Erkennen von Hypoglykämieängsten durch eine ausführliche Anamnese ist daher bedeutsam. Beim Vorliegen relevanter klinischer Symptome sollte zeitnah eine ambulante oder stationäre psychotherapeutische Behandlung erfolgen. Hierbei sollten die betroffenen Familien in die Lage versetzt werden, die Ängste zu bewältigen und das Diabetesmanagement möglichst unbelastet in ihren Alltag zu integrieren.